bpi glp-1 labs is challenging the tirzepatide patent. This is a second challenge as Empower pharmacy was already challenging the patent. BPI includes additional imformation including a previous patent application showing GLP-1/GIP as and intra GLP-ONE + Receptor Activator
Description
At low abundance (low fasting levels), GIP cannot fully occupy its receptor, potentially leaving the receptor available for exogenous tirzepatide
Nevertheless, as demonstrated in the STENO-2 trial, residual renal and risk and overall mortality remains high, also due to the fact that the different treatment targets are often not reached [4]
Background Incretins are gut-derived peptide hormones secreted after nutrient intake to enhance glucose-dependent insulin release from pancreatic -cells
Submit the form electronically through the designated platform
